The substantiation of the cost optimization for ER(+) HER2(−) breast cancer hormone therapy based on the results of the cost minimization pharmacoeconomic analysis
DOI:
https://doi.org/10.24959/sphhcj.25.349Keywords:
breast cancer; antiestrogens; aromatase inhibitors; pharmacoeconomic analysis of cost minimization.Abstract
Aim. To determine the most cost-effective drugs among aromatase inhibitors and antiestrogens used in hormone therapy regimens for the ER(+) HER2(−) breast cancer according to the results of the pharmacoeconomic analysis.
Materials and methods. The pharmacoeconomic analysis by the cost minimization method of hormone therapy regimens for patients with the ER(+) HER2(−) breast cancer using aromatase inhibitors and antiestrogens was performed.
Results. In order to determine the least expensive drugs among aromatase inhibitors and antiestrogens used for the treatment of the hormone-dependent breast cancer, a limited cost minimization analysis was conducted for 6 trade names (TNs) of anastrozole, 12 TNs of letrozole, 5 TNs of exemestane and among antiestrogens by international non-patent name (INN): tamoxifen, toremifene and fulvestrant, each of which is represented by 3 TNs. The indicator of a one-year course of treatment with drugs at average wholesale prices was calculated. The following drugs were determined as the ones with the least cost of a one-year course of treatment for the hormone-dependent breast cancer: among TNs of toremifene – Fareston tab., 60 mg, No. 60 (10493.49 UAH); among TNs of tamoxifen – Tamoxifen-Zdorovya tab., 10 mg, No. 60 (2071.56 UAH); among TNs of fulvestrant – Fulveject sol. for inj., 250 mg / 5 ml sirynge, No. 2 (81227.78 UAH); among TNs of letrozole – Letrozole-Vista AS film-coated tab., 2.5 mg (5907.19 UAH); among TNs of anastrozole – Anastrozole-Vista film-coated tab., 1 mg (7737.36 UAH); among TNs of exemestane – Exemarin sugar-coated tab., 25 mg (6 838.36 UAH).
Conclusions. Based on the results of the limited cost minimization pharmacoeconomic analysis conducted, the expediency of using drugs with the lowest cost for a one-year course of the hormone-dependent breast cancer treatment has been substantiated, provided that they are equally effective among aromatase inhibitors and antiestrogens. The inclusion of selected drugs in the list of public procurement provides an opportunity to optimize the costs for treating the hormone-dependent ER(+) HER2(−) breast cancer and optimally spend financial resources on healthcare.
References
Chen, S., Cao, Z., Prettner, K., Kuhn, M., Yang, J., Jiao, L., Wang, Z., Li, W., Geldsetzer, P., Bärnighausen, T., Bloom, D. E., & Wang, C. (2023). Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncology, 9(4), 465–742. https://doi.org/10.1001/jamaoncol.2022.7826
Kocarnik, J. M., Compton, K., Dean, F. E., Fu, W., Gaw, B. L., Harvey, J. D., Henrikson, H. J., Lu, D., Pennini, A., Xu, R., Ababneh, E., Abbasi-Kangevari, M., Abbastabar, H., Abd-Elsalam, S. M., Abdoli, A., Abedi, A., Abidi, H., Abolhassani, H., Adedeji, I. A., . . . Force, L. M. (2022). Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. JAMA Oncology, 8(3), 420–444. https://doi.org/10.1001/jamaoncol.2021.6987
Bray, F., Laversanne, M., Weiderpass, E., & Soerjomataram, I. (2021). The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(16), 3029–3030. https://doi.org/10.1002/cncr.33587
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74, 229–263. https://doi.org/10.3322/caac.21834
Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 66,15–23. https://doi.org/10.1016/j.breast.2022.08.010
Taylor, C., McGale, P., Probert, J., Broggio, J., Charman, J., Darby, S. C., Kerr, A. J., Whelan, T., Cutter, D. J., Mannu, G., & Dodwell, D. (2023). Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study. BMJ, 381, e074684. https://doi.org/10.1136/bmj-2022-074684
Caswell-Jin, J. L., Sun, L. P., Munoz, D., Lu, Y., Li, Y., Huang, H., Hampton, J. M., Song, J., Jayasekera, J., Schechter, C., Alagoz, O., Stout, N. K., Trentham-Dietz, A., Lee, S. J., Huang, X., Mandelblatt, J. S., Berry, D. A., Kurian, A. W., & Plevritis, S. K. (2024). Analysis of Breast Cancer Mortality in the US1975 to 2019. JAMA, 331(3), 233–241. https://doi.org/10.1001/jama.2023.25881
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210
Health and Economic Benefits of Breast Cancer Interventions. National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). An official website of the United States government. https://www.cdc.gov/nccdphp/priorities/breast-cancer.html
Nemchenko, A. S., & Podhaina, M. V. (2009). Farmakoekonomichna otsinka khimioterapev-tychnoho likuvannia khvorykh na rak endometriiu. Zaporozhskyi medytsynskyi zhurnal, 11(4), 96–99.
Matushchak, M. R., & Panfilova, H. L. (2023). Farmakoekonomichna otsinka ratsionalnosti zastosuvannia skhem khimioterapii, shcho mistiat imunoterapevtychni preparaty, u liku-vanni klasychnoi limfomy Khodzhkina. Farmatsevtychnyi zhurnal, (3), 68–81. https://doi.org/10.32352/0367-3057.3.23.07
Kosyachenko, K., & Rafalska, Y. (2023). Analysis of pharmaceutical supply of breast cancer patients. ScienceRise: Pharmaceutical Science, 3(43), 87–94.
Mishchenko, O. Ya., Greshko, Yu. I., Aristov, M. A., Adonkina, V. Yu., & Ostashko, V. F. (2021). Clinical and economic evaluation of the use of fulvestrant compared with chemotherapy for the treatment of patients with locally progressive or metastatic ER (+) HER2 (-) breast cancer: Ukrainian realities. PharmacologyOnLine, 3, 355–366.
Howell, S. J., Johnston, S. R. D., & Howell, A. (2004). The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Practice Research Clinical Endocrinology Metabolism, 18(1), 47–66. https://doi.org/10.1016/j.beem.2003.08.002
Robertson, J. F. R., Jiang, Z., Di Leo, A., Ohno, S., Pritchard, K. I., Ellis, M., Bradbury, I., & Campbell, C. (2019). A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 26(6), 703–711. https://doi.org/10.1007/s12282-019-00973-4
Nakaz MOZ Ukrainy “Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Rak molochnoi zalozy” No. 396 (2015, Cherven 30). https://dec.gov.ua/wp-content/uploads/images/dodatki/2015_396_RMZ/2015_396_YKPMD_RMZ.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
